David Passov to speak on the Benefits of Conducting Clinical Trials in Russia and Navigating the New Regulations to Optimize Clinical Trial Performance
SAN FRANCISCO, July 21, 2011 /PRNewswire/ -- ClinStar, LLC, an established CRO providing clinical research services in Russia and Eastern Europe to the pharmaceutical and biotechnology industry, announced today that President and CEO David Passov will speak at Marcus Evans 6th Annual Clinical Research in Emerging Countries conference July 28-29 in Miami, FL.
The paradigm of traditional drug development is shifting as more and more biopharmaceutical organizations look to emerging markets to reduce their clinical study timelines, and hence overall development costs, through more effective patient enrollment. During his presentation scheduled for Thursday, July 28 at 10:30 a.m., Mr. Passov will address the perceptions of emerging markets; consider the benefits of conducting clinical trials in Russia compared to other emerging countries; and explore how best to navigate the new clinical trial regulations in order to optimize clinical trial performance. Mr. Passov will also chair the first day of this year's conference.
The Marcus Evans Clinical Research in Emerging Countries conference, now in its 6th year, will offer a half day workshop on July 27 followed by two days of sessions led by pharmaceutical and biotechnology industry leaders. Marcus Evans Emerging Countries conference series is aimed at equipping industry professionals with necessary knowledge on critical globalization issues such as regulatory and legal compliance, training of personnel, overcoming cultural barriers, and clinical outsourcing opportunities.
About ClinStar, LLC
ClinStar is one of the most prominent CROs in the emerging markets of Eastern Europe and the Baltics, with more than 10 years of expertise in Phase I-IV clinical studies in multiple therapeutic areas. Headquartered in San Francisco, California, ClinStar manages studies from its offices in Russia, Ukraine and Belarus, with total staff of over 300 people. Its portfolio contains over 130 clinical trials conducted for US and European pharmaceutical and biotechnology companies. More information is available at www.clinstar.com.
SOURCE ClinStar, LLC